RecruitingPhase 1Phase 2NCT06697184

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.

Sponsor

BeOne Medicines

Enrollment

258 participants

Start Date

Jan 23, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma CLL MCL

Summary

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Sonrotoclax and a drug called Zanubrutinib for people with cll, chronic lymphocytic leukemia, and other related conditions. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSonrotoclax

Administered orally

DRUGZanubrutinib

Administered orally

Locations(17)

Moffitt Cancer Center

Tampa, Florida, United States

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Genesiscare St Andrews

Adelaide, South Australia, Australia

Cabrini Hospital Malvern

Malvern, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Rockingham Hospital

Cooloongup, Western Australia, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

Chu Dijon

Dijon, France

Chu Montpellier Hopital Saint Eloi

Montpellier, France

Iuct Oncopole

Toulouse, France

Queen Elizabeth Hospital

Birmingham, United Kingdom

St Jamess University Hospital

Leeds, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06697184

Related Trials

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT0702973722 locations

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT073424785 locations

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902631 locations

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT057241211 location